Tissue Biomarkers of Prognostic Significance in Hepatocellular Carcinoma

Pinato, David J.; Pirisi, Mario; Maslen, Lynn; Sharma, Rohini

doi:10.1097/pap.0000000000000029

Cited by 15 publications

(13 citation statements)

References 164 publications

(184 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…However, most of them are only in phase 1 or 2 stages, further studies are needed to determine whether these biomarkers can be translated from bench works to clinical settings. The effects of other biomarkers to predict the prognosis for HCC such as vascular endothelial growth factor (VEGF), Cyclin-dependent Kinases(CDK), β-catenin/Wnt pathway and microRNAs [15] have been controversial and again none of them has been applied to the clinical settings.…”

Section: Introductionmentioning

confidence: 99%

The Association of HMGB1 Expression with Clinicopathological Significance and Prognosis in Hepatocellular Carcinoma: A Meta-Analysis and Literature Review

Zhang

Han

et al. 2014

PLoS ONE

View full text Add to dashboard Cite

BackgroundHepatocellular carcinoma (HCC) is the fifth most common cancer, and it is the second most common cancer-related mortality globally. The prognostic value of high mobility group box 1 (HMGB1) remains controversial. The purpose of this study is to conduct a meta-analysis and literature review to evaluate the association of HMGB1 expression with the prognosis of patients with HCC.MethodsA detailed literature search was made in Medline, Google Scholar and others for related research publications. The data were extracted and assessed by two reviewers independently. Analysis of pooled data were performed, Hazard Ratio (HR) and mean difference with corresponding confidence intervals (CIs) were calculated and summarized respectively.Results10 relevant articles were included for this meta-analysis study. HMGB1 mRNA levels in HCC were significantly higher than those in normal (p<0.00001) and para-tumor tissues (p = 0.002) respectively. The protein levels of HMGB1 in HCC were significantly higher than those in para-tumor tissues (p = 0.005). Two studies reported the serum HMGB1 levels in patients with HCC of TNM stages, and indicating significantly different between stage I and II, stage II and III, as well as stage III and IV (two studies showed p<0.01 and p<0.001 respectively). The overall survival (OS) was significantly shorter in HCC patients with high HMGB1 expression compared those with low HMGB1 expression and the pooled HR was 1.31 with 95% CI 1.20–1.44, Z = 5.82, p<0.0001. Two additional studies showed that there were higher serum HMGB1 levels in patients with chronic hepatitis than those in healthy people (p<0.05).ConclusionsThe results of this meta-analysis suggest that HMGB1 mRNA and protein tissue levels in the patients with HCC are significantly higher than those in para-tumor and normal liver tissues respectively. Tissue HMGB1 overexpression is a potential biomarker for HCC diagnosis, and it is significantly associated with the prognosis of patients with HCC.

show abstract

Section: Introductionmentioning

confidence: 99%

The Association of HMGB1 Expression with Clinicopathological Significance and Prognosis in Hepatocellular Carcinoma: A Meta-Analysis and Literature Review

Zhang

Han

et al. 2014

PLoS ONE

View full text Add to dashboard Cite

show abstract

“…Surgical resection and liver 17 transplantation are two promising treatment strategies for HCC, 18 however, the clinical outcome of patients remains poor, with a 19 median survival of 6-9 months following diagnosis [3]. Especially 20 for advanced-stage HCC patients, the 5-year overall survival rate is 21 less than 5% due to high recurrence and metastasis rates 22 [4]. Growing evidence show that it is a complex and multi-step 23 process of hepatocarcinogenesis which is associated with various 24 genetic and epigenetic changes [5,6].…”

mentioning

confidence: 99%

MicroRNA-708 is downregulated in hepatocellular carcinoma and suppresses tumor invasion and migration

Yang

et al. 2015

Biomedicine & Pharmacotherapy

View full text Add to dashboard Cite

“…The alteration of the target gene expression level leads to the abnormality of the corresponding protein function, which is the critical mechanism underling the hepatocarcinogenesis [11][12][13]. Based on the sample size, we combined the data of stage III and IV, and focused on the differentially expressed genes associated with normal, stage I, stage II, and stage III-IV classi cations.…”

Section: Discussionmentioning

confidence: 99%

Genetic Expression and Mutation Profile Analysis in Different Pathologic Stages of Hepatocellular Carcinoma Patients

et al. 2020

View full text Add to dashboard Cite

Background: The expression and mutation of multiple genes are involved in the complicated mechanism regarding the occurrence and development of hepatocellular carcinoma (HCC). The clinical pathological stage of HCC is closely linked to clinical prognosis of liver cancer. This study aims at analyzing the gene expression and mutation pro le of different clinical pathological stages of HCC (stage I, II, III-IV), based on 367 HCC cases included in TCGA cohort. Results: We identi ed a series of targeting genes with copy number variation (CNV), which is statistically associated with gene expression. For instance, compared withthe normal group, CCNE2 gene is highly expressed in the tumor group and speci cstage I group, which are associated withthree CNV types of single deletion, single gain, and ampli cation mutations. Protein interaction network construction and followed "Molecular Complex Detection" analysis indicated that the high expression of some cell cyclerelated genes in HCC, such as TTK, CDC20, ASPM, is positively correlated with CNV. Non-synonymous mutations mainly existed in some genes, such as TTN, TP53, CTNNB1, MUC16, andALB, however, we did not observe the association between thegene mutation frequency and the clinical pathological grade distribution. The rs121913396 and rs121913400 polymorphisms withintheCTNNB1 gene were associated with the high expression of CTNNB1 protein, but not linked to the clinical prognosis of HCC. We performed the random forest and decision tree approachesfor the modeling analysis and identi ed a group of genes related to different HCC pathological grades, such as the lowly expressed VIPR1, FAM99A, and GNA14 genes, or highly expressed CEP55, SEMA3F, and PRR11. Moreover, we conducted a principal component analysis (PCA) to obtain several genes associated with different pathological grades, including SLC27A5, ADAM17, SNRPA, SNRPD2, and ALDH2. Finally, we con rmed the highly expressed GAS2L3, SNRPA, SNRPD2 genes in the HCC tissues, for the rst time, through a Chinese HLivH060PG02 cohort analysis. Conclusions: The identi cation of the targeting genes, including GAS2L3, SNRPA, SNRPD2, provides insight into the molecular mechanisms associated with different prognosis of HCC.

show abstract

Tissue Biomarkers of Prognostic Significance in Hepatocellular Carcinoma

Cited by 15 publications

References 164 publications

The Association of HMGB1 Expression with Clinicopathological Significance and Prognosis in Hepatocellular Carcinoma: A Meta-Analysis and Literature Review

The Association of HMGB1 Expression with Clinicopathological Significance and Prognosis in Hepatocellular Carcinoma: A Meta-Analysis and Literature Review

MicroRNA-708 is downregulated in hepatocellular carcinoma and suppresses tumor invasion and migration

Genetic Expression and Mutation Profile Analysis in Different Pathologic Stages of Hepatocellular Carcinoma Patients

Contact Info

Product

Resources

About